Abasaglar ® (basal insulin glargine)

This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information: Abasaglar Summary of Product Characteristics (SmPC)

Abasaglar® (insulin glargine): Cancer incidence

None of the neoplasm events in the Abasaglar (insulin glargine) phase 3 clinical studies was deemed related to study drug.

Detailed Information

None of the neoplasm events in the phase 3 ELEMENT-1, ELEMENT-2 and ELEMENT-5 clinical studies for Abasaglar were considered by the investigator to be possibly related to the study drug.1

In the phase 3 studies that compared Abasaglar with Lantus, there were no statistically significant differences in the incidence of neoplasms between treatment groups (Table 1. Neoplasms Reported in the ELEMENT-1 Clinical Study for Abasaglar  ,Table 2. Neoplasms Reported in the ELEMENT-2 Clinical Study for Abasaglar  and Table 3.  Neoplasms Reported in the ELEMENT-5 Clinical Study for Abasaglar ).1

Table 1. Neoplasms Reported in the ELEMENT-1 Clinical Study for Abasaglar 1

Neoplasms, n (%)

Abasaglar
(n=268)

Lantus
(n=267)

p-Value

Neoplasms benign, malignant, and unspecified (including cysts and polyps)

1 (0.4)

5 (1.9)

p=.123

Skin papilloma

1 (0.4)

1 (0.4)

 

Gliomatosis cerebri

0 (0.0)

1 (0.4)

 

Refractory cytopenia with unilineage dysplasia

0 (0.0)

1 (0.4)

 

Squamous cell carcinoma

0 (0.0)

1 (0.4)

 

Uterine leiomyoma

0 (0.0)

1 (0.4)

 

Abbreviations: Abasaglar = Abasaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL.

Table 2. Neoplasms Reported in the ELEMENT-2 Clinical Study for Abasaglar1

Neoplasms, n (%)

Abasaglar
(n=376)

Lantus
(n=380)

p-Value

Neoplasms benign, malignant, and unspecified (including cysts and polyps)

5 (1.3)

3 (0.8)

p=.503

Squamous cell carcinoma

1 (0.3)

1 (0.3)

 

Adrenal adenoma

1 (0.3)

0 (0.0)

 

Bladder cancer

0 (0.0)

1 (0.3)

 

Fibroadenoma of breast

1 (0.3)

0 (0.0)

 

Lung adenocarcinoma

1 (0.3)

0 (0.0)

 

Lung carcinoma cell type unspecified recurrent

1 (0.3)

0 (0.0)

 

Thyroid neoplasm

0 (0.0)

1 (0.3)

 

Abbreviations: Abasaglar = Abasaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL.

Table 3.  Neoplasms Reported in the ELEMENT-5 Clinical Study for Abasaglar1

Neoplasms, n (%)

Abasaglar
(n=249) 

Lantus
(n=244) 

p-Value  

Neoplasms benign, malignant, and unspecified (including cysts and polyps) 

2 (<1) 

 3 (1.2)

.683 

Benign neoplasm of thyroid gland 

0 (0) 

2 (<1) 

.244 

Adenocarcinoma of colon

1 (<1)

0 (0) 

1

Adrenal adenoma

1 (<1)

0 (0) 

1

Chronic myeloid leukaemia

0 (0) 

1 (<1)

0.495

Skin papilloma

1 (<1)

0 (0) 

1

Abbreviations: Abasaglar = Abasaglar® (insulin glargine) 100 units/mL; Lantus = Lantus® (insulin glargine) 100 units/mL.

References

1. Data on file, Eli Lilly and Company and/or one of its subsidiaries.

Glossary

Abasaglar = Abasaglar® (insulin glargine) 100 units/mL

ELEMENT-1 = a prospEctive, randomized, open-LabEl coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in combination with mealtime insulin lispro in adult patiENTs with type 1 diabetes mellitus

ELEMENT-2 = a prospEctive, randomized, doubLE-blind coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in adult patiENTs with type 2 diabetes mellitus

ELEMENT-5 = a prospEctive, randomized, open-LabEl coMparison of a long-acting basal insulin analog LY2963016 to Lantus® in adult patiENTs with type 2 diabetes mellitus

Lantus = Lantus® (insulin glargine) 100 units/mL

Date of Last Review: August 08, 2018

Contact Lilly

Call or Email us

If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com

Available Mon - Fri, 8am - 4pm, excluding Bank Holidays

Or you can

Ask us a question Chat with Us If you have a question, you can chat online with a Lilly Medical Information professional.

Submit a question